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In recent years several authors have reported the 
appearance of diabetes after construction of portacaval 
anastomosis (PCA) in patients with hepatic cirrhosis.(1-4) 
Seven cases have been reported in which diabetes appeared 
from five to 19 months after creation of a PCA. (Table 1) 
Recently much evidence has been published calling 
attention to the too frequent coexistence of diabetes 
and hepatic cirrhosis. A number of investigators have 
reported the presence of diabetes in 11-35% of their 
patients with cirrhosis. (5-13) 
A number of features commonly associated with chronic 
liver disease, especially Laennec’s cirrhosis, might be 
responsible for the diabetes seen in cirrhosis. Theore¬ 
tically, one might expect to see several different patho¬ 
genetic types of diabetes. Some of these may be classi¬ 
fied as follows: 
Hepatogenous Diabetes Injury to hepatic parenchymal 
cells might lead to altered carbohydrate metabolism. Both 
hyperglycemia and hypoglycemia have been observed in 
chronic hepatic injury presumably secondary to impaired 
glucogenesis and glycogenolysis respectively. Conn and 
Newbergh have observed hypoglycemia and impaired glucose 
tolerance in patients with chronic cholangitis. (14) 
A reversible transient diabetic state has been described 
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by Leevy in patients with fatty infiltration of the liver 
secondary to alcoholism which disappeared with improve- 
ment in liver function and recurred with resumption of 
alcohol ingestion. (15) 
Pancreatitic Diabetes Pancreatitis, often silent, 
is a well known concomitant of alcoholic cirrhosis. It 
has been estimated to be present in one-third of cirrhotic 
patients. (16) It has also been observed that acute 
pancreatitis may be associated with transient diabetes, 
(17) and that chronic pancreatitis can result in per¬ 
manent decrease in insulin secretory capacity secondary 
to beta cell injury.(18) Diabetes may thus develop in 
cirrhotic patients as a consequence of inflammatory 
injury to the islet cells, i.e. not actually as a result 
of the liver disease per se. 
Memo siderotic Diabetes Diabetes is one of the tra¬ 
ditional components of idiopathic hemochromatosis. It is 
thought to be secondary to the deposition of excess 
hemosiderin in the islet cells. While the syndrome of 
idiopathic hemochromatosis does not appear very often in 
alcoholic cirrhosis, increased hepatic iron deposition is 
common in this disease.(19) Pancreatic hemosiderin 
deposition while much less common in cirrhosis occurs 
with sufficient frequency to warrant serious consideration 
as a cause of diabetes. Furthermore, full blown nemo- 
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chromatotic syndrome has been shown to occur shortly 
after construction of a portacaval shunt.(20) 
Insulin-resistant Diabetes Insulin resistance has 
been demonstrated to occur in cirrhosis.(21) Megyesi 
suggested that chronic hepatic disease produces endo¬ 
genous insulin resistance and hyperinsulinism which may 
eventually lead to beta cell exhaustion and insulin 
deficiency.(22) Samaan observed that cirrhotic patients 
with normal or slightly abnormal glucose tolerance showed 
a greater hyperinsulinemic response to oral glucose 
administration than cirrhotics with grossly abnormal 
glucose tolerance. He interpreted this insulin resis¬ 
tance to be the key defect in the development of diabetes 
and implied that patients may develop diabetes when they 
are no longer able to satisfy the increasing demand for 
insulin.(23) The cause of the insulin resistance is not 
evident but might be related to elevated free fatty acids 
which are present in cirrhosis,(24,25) or to hypersomato- 
trooism. 
So mat o t r o p i c Diabetes Acromegaly is associated V7ith 
increased frequency of diabetic carbohydrate intolerance 
and peripheral insulin resistance. Administration of ex¬ 
ogenous growth hormone may induce these abnormalities.(26) 
Growth hormone has been shown to be elevated in some 
cirrhotic patients.(27) It is conceivable that hyper- 
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somatotropism may precipitate diabetes in susceptible 
patients with cirrhosis, iso cause for the elevated growth 
hormone levels has been identified. 
Kaliooenic Diabetes Potassium depletion has been 
shown to be a predisposing factor in the development of 
diabetes. It has been observed that approximately 507® of 
patients with primary aldosteronism have impaired glucose 
metabolism. This defect in carbohydrate metabolism has 
been reversed by either removing the tumor or replacing 
potassium losses.(28) Patients with alcoholic cirrhosis 
almost always have a sizeable potassium deficit due to a 
combination of factors among which are poor dietary in¬ 
take, fluid losses from vomiting and diarrhea, potassium 
losing diuretics, and coincidence of secondary aldoster¬ 
onism. (29) Thus secondary aldosteronism, like primary 
aldosteronism, through its associated potassium depletion, 
may precipitate diabetes. 
Genetic Diabetes A certain percentage of any group 
of patients will have a genetic predisposition toward the 
development of diabetes, and will go on to develop the 
disease in the absence of any secondary precipitating 
factors. It has been shown that there is a greater genetic 
predisposition to the development of diabetes among 




The appearance of diabetes after PCA has been an 
inconstant observation. It has been reported that no 
significant changes in carbohydrate metabolism can be 
found in cirrhotic patients after PCA.(31) Several studies 
dealing with the purely surgical asoects of PCA dealing 
with large numbers of patients have only casually mentioned 
diabetes as a complication of PCA.(32-34) 
Host of the data relating diabetes to PCA are in the 
form of retrospective observations. A common definition 
of diabetes is lacking, and in many cases the criteria 
used in making the diagnosis of diabetes are not spe¬ 
cified. Ho controlled study of this association has been 
reported. In most reports consideration of the poten¬ 
tially diabetogenic factors found in cirrhosis is not 
seen. 
The present study was Derformed to determine in a 
prospective, controlled fashion, whether or not PCA in¬ 
creases the incidence of diabetes, and if so to attempt to 
elucidate contributing pathogenetic mechanisms. The 
patients included in several ongoing, prospective inves¬ 
tigations of prophylactic PCA provided an ideal group of 
patients in which to evaluate these phenomena. 
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MATERIALS AND METHODS 
The patients used in this investigation were those 
patients studied by Conn and Lindenmuth in their con¬ 
trolled prospective investigations of prophylactic 
portacaval anastomosis in the treatment of cirrhotic 
patients with esophageal varices. (35,36) These studies 
were undertaken to determine the effect of PCA on long 
term survival of patients with cirrhosis and esophageal 
varices who had not previously bled from their varices. 
All patients included in these studies satisfied strict 
criteria for admission, and once included, were random¬ 
ized into separate groups, one of which served as control 
for the other group which had portacaval sunt operations. 
Thus im planning such a study there are two groups of 
patients whose only apparent difference is that one had 
the operative procedure while the other did not. 
The studies were conducted as two separate investi¬ 
gations over a period of 13 years. The patients studied 
were all men who had been admitted to the Jest Haven 
Veterans Administration Hospital (WHVAH). Prophylactic 
Shunt Study 1 (PSS-J) included patients admitted between 
September 1, 1953 and June 1, 1963. The criteria for 
admission to this study were as follows: 
1) a histologic diagnosis of cirrhosis. 
2) esophagoscopic demonstration of esophageal varicew. 
t 
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3) splenic pulp pressure exceeding 200 mm. H20. 
4) no previous history of hemorrhage from varices. 
5) patients had to be considered good operative risks 
During this period approximately 250 cirrhotic 
patients were admitted to the hospital. Of the survivors 
who had not previously bled from varices, 68 were shown 
to have esophageal varices. Eight were considered poor 
operative risks and were excluded from the study because 
of severe non-hepatic disorders such as cardiovascular 
decompensation and pulmonary insufficiency. These 
patients constitute the Exclusion Group 1, Ho patients 
were excluded from the study because of the severity 
of their liver disease. 
The remaining 60 patients were selected for inclu¬ 
sion in the clinical trial. After inclusion each patient 
was chosen by random selection to have a portacaval shunt 
or to be an unoperated control patient. Control Group I 
consists of 31 patients chosen to be control patients. 
Twenty-nine were chosen to have portacaval anastomoses. 
Four refused and comprised Refusal Group I. The remaining 
25 patients constitute Shunt Group I. End-to-side 
portacaval anastomoses were constructed in 21, and side-to 
side anastomoses in four. 
This investigation (PSS-1) showed that survival 
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was not increased by prophylactic PGA. It was observed 
however, that all patients who bled from varices in this 
study had had overt ascites at the time of inclusion. 
Consequently a second study was undertaken of cirrhotic 
patients with varices and ascites. Prophylactic Shunt 
Study-XI (PS3-II) included patients admitted from 
January 1, 1965 to December 31, 1970. The criteria for 
admission to PSS-II are similar to those of PSS-I: 
1) a histologic diagnosis of cirrhosis, 
2) esoohagosconic demonstration of esophageal 
varices. 
3) splenic pulp pressure exceeding 250 mm H20 at 
time of inclusion. 
4) no previous history of hemorrhage from varices. 
5) patients had to be considered good operative 
risks, 
6) patients must have had overt ascites, defined as 
abdominal distension accompanied by shifting 
flank dullness of at least 8 cm. during the 
hospital admission; a history of prior ascites 
must have been documented by paracentesis or 
other unequivocal proof. 
7) patients who had reached their sixty-fifth 
birthday were excluded in order to mi imize 
the incidence of portal-systemic encephalopathy 
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which occurs most commonly in elderly patients. 
Approximately 360 new patients with cirrhosis were 
admitted to the WHVAH during the time of PSS-II. Of 102 
cirrhotic patients with esophageal varices who had not 
previously bled from varices, 26 were excluded (Exclusion 
Group II), 9 on the basis of age, 7 because of splenic 
pulp pressure levels less than 250 mm. H2O, 2 with severe 
portal-systemic encephalopathy, and 8 with severe non- 
hepatic disorders which made them poor operative risks. 
Thirty-three who did not have ascites comprise the Eon- 
Ascitic Group. Forty three satisfied all criteria for 
admission and were randomized. Twenty-two were selected 
to have prophylactic portacaval shunts. Two refused and 
constitute Refusal Group II. Portacaval shunts were per¬ 
formed in the remaining 20 (Shunt Group II). Twenty-one 
patients comprise Control Group II. 
The various groups of patients were similar in age, 
in the duration of symptoms of cirrhosis, in the type and 
severity of cirrhosis, in liver function, and in the 
physical signs of cirrhosis. ( Tables 2-7 and Figures 1-2* ) 
Ascites had been present in about two thirds at the time 
of inclusion. The splenic pulp pressures and ammonia 
tolerance test were similar in the Control and Prophylactic 
Shunt Groups. The magnitude of varices, determined 
endoscopically was similar in the two groups. 
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One additional group of patients was also studied. 
This group includes 48 patients from the WHVAH who had 
bled previously from esophageal varices and were therefore 
not eligible in the prophylactic portacaval shunt study. 
These patients all of whom had a histologic diagnosis of 
cirrhosis, had therapeutic portacaval shunts performed and 
comprise the Therapeutic Fortacaval Shunt Group. Therapeu¬ 
tic shunt patients are included to provide data on an 
additional group of portacaval shunts performed at this 
hospital. The similarity between the prophylactic and 
therapeutic shunt patients with regard to age, severity of 
cirrhosis, including physical signs and liver function 
tests permits combination of these groups. 
The charts of all patients were reviewed and the 
following information extracted: 
1) age, sex, and history of diabetes in the immediate 
family (siblings, parents or grandparents). 
2) etiology of cirrhosis, 
3) date of initial appearance of signs of cirrhosis. 
4) liver function tests before and after inclusion 
or shunt. 
5) physical signs of cirrhosis before and after 
inclusion or shunt. 
6) splenic pulp pressure. 
7) history of alcohol intake including the nature 
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of the beverage imbibed in the greatest 
amount, 
8) presence of pancreatitis as determined by serum 
amylase and lipase activity and autopsy findings, 
9) presence of hemochromatosis or any iron storage 
disorder as determined from clinical findings 
as V7ell as serum iron, iron binding capacity, 
and iron deposition in liver, bone marrow and 
other tissues at biopsy and/or autopsy, 
10) fasting serum glucose levels before and after 
inclusion in control patients, and before and 
after shunt for operated patients. In most 
cases many fasting glucose levels were recorded 
at frequent intervals after inclusion and through¬ 
out folLow-up periods as well as before inclu¬ 
sion, for every hospital admission in the chart. 
11) results of glucose tolerance tests, urinalyses 
for glycosuria, both before and after inclusion 
or shunt. 
Additional data gathered on patients classified as having 
diabetes included 
12) date of initial recognition of diabetes. 
13) therapy employed in treatment of diabetes. 
Diagnosis of Diabetes . Diabetes was defined as 
persistent fasting hyperglycemia, all serum glucose levels 
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greater than 140 mg./ 100 ml. (AutoAnalyzer ferricyanlde 
method). Each patient so classified must have had at least 
two such analyses each of which was greater than 140 mg./ 
100 ml. Glucose tolerance tests were not used as diagnos¬ 
tic criteria since oral glucose toleramce has been shown 
to be abnormal in the majority of cirrhotic oatients.(37) 
Chi square statistical analyses were all performed 




Incidence of Diabetes at Inclusion. (Tables 8-10) 
A total of 214 patients were studied of whom 
20 (9.2%) had diabetes as defined previously. 
Non-shunt Patients at Time of inclusion. At inclusion 
in Control Group I, 31 patients were studied, of whom 
2 (6.5%) had diabetes. Of 21 patients in Control Group II, 
1 (4.7%) had diabetes. The difference between these two 
groups is not statistically significant (p> 0.5). Conse¬ 
quently the two control grouos have been combined into a 
single control group (Control Group I-II), A total of 69 
other non-operated patients assigned to Exclusion Groups 
I-1I, Refusal Groups I-II, and Non-Ascitic Group, were 
united into the Combined Exclusion Group. Seven of these 
69 patients (10,27a) had diabetes. The incidence of diabetes 
at the time of inclusion in Control Group I-II and the 
Combined Exclusion Group did not differ significantly. 
Therefore they have been combined into the single Non- 
Operated Group which consists of 121 patients, 10 of 
whom (8.3%) had diabetes at the time of inclusion. 
Shunt Patients at Time of Inclusion. At the time of 
inclusion Shunt Group I included 25 patients, none (0%) of 
whom had diabetes. Shunt Group II included 20 patients, of 
whom 3 (15%,) had diabetes. The difference between these 
two groups is not significant statistically. The two shunt 
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groups have been combined into Shunt Group I-II, which 
includes 45 patients at inclusion of whom 3 (6.67o) had 
diabetes. 
At inclusion, 8 (16.7%) of 48 patients in the 
Therapeutic Shunt Group had diabetes. The frequency of 
diabetes in this group was slightly higher, but not sig¬ 
nificantly higher, than in Shunt Giroup I-II (p> 0.05). 
The two have been combined to form a single Operated Group 
which consisted at the time of inclusion of 93 patients 
of whom 11 (11.8%) had diabetes. 
Comparison of the Frequency ojE Diabetes in Operated 
vs. Non-Operated Groups at Time of Inclusion. At the time 
of admission to the study therefore, there were 121 
patients in the Nor-Operated Group of whom 10 (8.3%) had 
diabetes compared with 93 in the Operated Group of whom 
11 (11.8%) had diabetes. This difference is not signifi¬ 
cant statistically. 
Incidence of Diabetes during Follow-up. (Tables 8-10) 
Of 214 patients included at the beginning of the study 
175 (82%) were followed for at least 6 months. Almost all 
of those not followed were patients who died within 6 
months of inclusion into the study. Of the 175 patients so 
followed, 13 (10,3%) had diabetes at the time of inclusion. 
Diabetes was present at inclusion in 8 of the 103 
( 7.8%) Non-Qperated patients. Similarly the prevalence 
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of diabetes was 12.5% (10 of 72) in the Operated Group. 
The 103 patients in the Non-Operated Group were 
followed for an average of 44.5 months (range, 6 to 147 
months). At the end of the period of observation, 16 
(15,5%) had diabetes. Thus, 8 additional patients had 
developed diabetes during this period. 
The 72 patients in the Operated Group were followed 
for an average of 39.8 months,(range, 6 to 141 months). 
At the end of the study 21 (37.3%) had diabetes. Eleven 
additional patients had developed diabetes during the 
period of observation. 
If one compares the new cases of diabetes which 
appeared during the period of follow-up, (3 of 95 at 
'V 
risk in the Non-Operated Group vs. 11 of 62 at risk in 
the Operated Group) the difference is not significant 
statistically. (V* - 3.75 d> 0.05) 
At the end of the study, 16 of 103 patients (15.5%) 
in the Kon-Opesated Group had diabetes as did 21 (29%) of 
72 ixi the Operated Group. The difference between these 
two groups is statistically significant. = 3,94 p<0.05) 
Of 103 patients in the group, 3 had diabetes at 
inclusion, Therefore only 95 (103-3) were at 
risk of developing diabetes during follow-up. 
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Comparison of Features of Cirrhosis in Operated and Non- 
Operated Groups at Time of Inclusion. 
As seen in Tablell the Mon-Operated Group did not 
differ significantly from the Operated Group in the clin¬ 
ical features of cirrhosis at the time of inclusion. In 
both groups the etiology of cirrhosis was almost exclusive¬ 
ly alcoholic. The mean age of non-ooerated patients was 
51.0 years, and that of operated patients was 50.5 years. 
Physical findings and laboratory values at the time of 
inclusion were similar. Practically all had hepatomegaly. 
Approximately half vere jaundiced and two thirds had 
spider angiomata. About two thirds also had ascites. Liver 
function tests were also similar in the groups. The mean se¬ 
rum albumin levels were 2.3 gm./100ml. in the Mon-Operated 
and 3.0 gm./lOO ml. in the Operated Group. Mean SCOT 
levels were 52,0 and 47.5 Reitman-Frankel units respec¬ 
tively. Alkaline phosphatase levels were similar in the 
two groups. 
A positive family history of diabetes in the 
immediate family was found in 15 patients (14.6%), in 
thethe Mon-Operated Group, and in 20 (27.8%) im the 
Operated Group. This difference is significant statisti¬ 
cally (ya~3,84 p< 0.05). 
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Comparison of Features of Cirrhosis in Diabetic and 
Hon-Diabetic patients. 
Comparing all diabetic patients in this study with 
all non-diabetic patients, we see in Table 12 that in 
most respects the two groups are similar. The mean age at 
inclusion is similar. Physical signs of cirrhosis and 
liver function studies were also similar in diabetic and 
non-diabetic patients. 
A positive family history of diabetes in the imme¬ 
diate family was noted in 12 (31.47®) of diabetics and 
in 25 (18.1%) of non-diabetics. This difference is not 
significant (X1-* 2.78 p> 0.05) 
Appearance of Pancreatitis and Hemosiderosis in the 
Various Groups. (^able 14) 
Pancreatitis was found in 4 (3.97.) of Non-Operated 
Group patients and in 6 (8.3%) of the Operated Group. 
This difference is not significant, excessive hepatic 
hemosiderin deposits were found in 3 (2.9%) of non-operated 
patients and 4 (5.6%) of operated patients. Again, this 
difference is not significant . 
Comparing diabetic and non-diabetic patients -we 
find that pancreatitis was present in 2 (5.47®) of diabetic 
patients and in 8 (5.8%) of non-diabetics. This difference 
is not significant. 
Hepatic hemosiderosis was found in 4 (10.8%) of 

of 37 patients compared with only 3 (2.2%) of 




The evidence here suggests that there is a relation¬ 
ship between the surgical creation of a portacaval 
anastomosis and the development of diabetes. The data 
are derived from two groups of cirrhotic patients similar 
in nearly all respects, including the prevalence of diabetes, 
before surgical intervention. At the conclusion of the 
period of observation, diabetes was more common in the 
operated patients. These most interesting observations 
raise a number of questions, the answers to which might 
help to explain the pathogenesis of the diabetes of cirrhosis. 
Diabetes mellitus is a generalized chronic metabolic 
disorder which usually develops in subjects with a heredi¬ 
tary predisposition, and is manifested in its fully deve¬ 
loped form by weakness, lassitude, loss of weight, and by 
hyperglycemia, glycosuria, ketosis, acidosis, and protein 
breakdown. Secondary abnormalities of small blood vessels 
may appear, and ultimately cause renal failure, blindness, 
neuritis, hypertension, and congestive heart failure. 
Current classification divides diabetes into a pri¬ 
mary type of unknown cause, and an acquired secondary 
type,(33) Primary diabetes is the more common of the two. 
It is a familial disorder characterized by abnormal 
carbohydrate metabolism and degenerative vascular disease, 
resulting from a relative or absolute insulin 
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deficiency. It is a relatively stable disease which usually 
occurs in overweight individuals, and may exist for long 
periods of time without symptoms. Although they have a 
mild form of the disease they are relatively resistant to 
insulin, but paradoxically usually do not require exo¬ 
genous insulin therapy, and will on most cases remain 
stable on dietary theraoy alone, rarely developing ketosis. 
Secondary diabetes is considered to be an acquired 
form of the disease in which alterations exist that mimic 
the primary state, but which are secondary to an organic 
dysfunction which becomes responsible for a relative or 
absolute insulin deficiency. These various etiologies 
have been classified as follows: 
1) Hyperadrenalism, cortical- as see in Cushing's 
syndrome and primary aldosteronism; and 
medullary- as seen in pheochromocytoma. 
Although hepatic corticosteroid metabolism is 
decreased in patients with liver disease, endo¬ 
genous production by the adrenals tends to 
slow, oresumably to maintain normal circulating 
levels. (39) 
2) Hyperpituitarism. acromegaly, pituitary baso¬ 
philism, and therapy with adrenocorticotropic 
hormone and somatotropin as examples. 
3) Hyperthyroidism. evidenced by thyrotoxicosis 
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thyroid therapy which are rare causes of 
clinical diabetes. We have found neither 
clinical signs nor laboratory evidence of 
hyperthyroidism in our cirrhotic patients. 
4) Destruction of islet cell tissues as seen in 
hemochromatosis, pancreatitis, cystic or neo* 
plastic pancreatic disease and surgical 
removal of pancreatic tissue. 
The acquired type of diabetes is not nearly as 
likely to produce degenerative changes, and when it does, 
these are much less advanced than those commonly found 
in the primary form of the disease. Patients with secon¬ 
dary diabetes as a rule have a lower incidence of a pos¬ 
itive family history of diabetes. This form of the 
disease is frequently associated with remission and if 
it is practicable to remove the cause of secondary 
diabetes, e.g. cessation of cortocosteroid therapy, a 
cure of the diabetes may be anticipated. 
The diagnosis of diabetes may be suspected through 
recognition of the common clinical signs associated with 
it and confirmed through a number of laboratory determina¬ 
tions, Abnormal glucose tolerance may be recognized before 
the clinical appearance of diabetes and before persistent 
elevation of fasting blood glucose levels. As mentioned 
previously, oral glucose tolerance is abnormal in the 
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majority of non-diabetic cirrhotic patients.(37) Although 
the mechanism of the impaired glucose tolerance is not 
known, it is probable that the conventional diagnostic 
criteria for diabetes are not applicable to cirrhotic 
patients. We have arbitrarily decided, therefore, that 
the oral glucose tolerance test is unsuitable as a diag¬ 
nostic criterion for our purposes, and have defined 
diabetes as persistent fasting serum glucose levels 
greater than 140 rng./lOO ml. (this is equivalent to 
approximately 120 mg./lOO ml. for whole blood determina¬ 
tions). By choosing these more rigid criteria we have in¬ 
sured that only severe disturbances of glucose metabolism 
will be classified as diabetes. 
What Tyne oj! Diabetes is Found in Chronic Liver Disease? 
Many observers have reported an increased incidence 
of diabetes in patients with cirrhosis.(5-13) There is 
evidence for both the primary and secondary types of 
diabetes in such oatients. Conn in 1969 observed diabetes 
as defined by fasting hyperglycemia greater than 140 mg./ 
100 ml. (serum) in 16.7% of 240 patients with predominantly 
alcoholic cirrhosis, as opposed to 7% of a random sample 
of non cirrhotic patients in the same hospital.(5) He 
observed that 46% of the cirrhotic-diabetic patients had 
a positive family history of diabetes in the immediate 
family. He also noted that among cirrhotic patients 
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without diabetes the incidence of a positive family 
history was 16% which is far higher than one would ex¬ 
pect to find in a random group. These observations 
suggest that many cirrhotic patients who develop diabetes 
may be genetically predisposed to do so. Far more intri¬ 
guing is the implication that patients with a predisposi¬ 
tion to diabetes may also be unusually susceptible to 
the development of cirrhosis. 
As discussed above, other disorders may lead to the 
development of secondary diabetes associated with chronic 
hepatic disease. In his series, Conn reported that several 
of his patients had pancreatitis, and assumed that those 
patients with transient diabetes, had diabetes which was 
secondary to pancreatitis. In at least one patient in 
this series, the diabetes was thought to be secondary to 
hemochromatosis. 
Conceptually the diabetes of cirrhosis may develop 
in one of three general eays. First there is diabetes of 
purely genetic origin, i.e. primary diabetes which v:ould 
ultimately appear without any of the additional diabeto¬ 
genic stimuli associated with chronic liver disease. 
Secondly, diabetes may develop in those patients 
with a genetic predisposition in whom diabetogenic stimuli 
such as pancreatitis or hemosiderosis are present. The 
association of increased iron absorption with either 
pancreatitis or PCA for example,(40,41) shows how these 
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factors may interact. The patient with a positive family 
history of diabetes who becomes overtly diabetic shortly 
after PGA, and is also found to have moderately increased 
iron deposition in the liver on subsequent biopsy may 
fall into this category. It is conceivable that the 
hypothetical factor which is responsible for primary 
diabetes may be potentiated after the construction of 
a PCA. 
Thirdly, patients with chronic liver disease without 
genetic predisposition to diabetes may develop diabetes 
as a consequence of discrete organic dysfunction associated 
with liver disease. Conn found several patients with 
diabetes and oancreatitis, whose diabetes disappeared 
within one year thereafter.(5) Pure, irreversible, 
secondary diabetes may occur with hemosiderosis alone or 
with chronic fibrosing pancreatitis, in the absence of 
genetic predisposition. 
Having defined diabetes, and having discussed the 
multitude of variables which may play a role in the 
development of the diabetes in cirrhosis we can now turn 
to our data. 
Were the Operated and Mon-Operated Groups of patients 
Truly Similar2 
As seen in Table llat the time of inclusion into 
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the study the cirrhosis was approximately equally advanced 
in tne two groups as measured by the similarity of labora¬ 
tory values and physical signs of the disease. These fea¬ 
tures were also similar at the end of the period of obser¬ 
vation. 
Furthermore there was no statistically significant 
difference in the Drevalence of pancreatitis in the two 
$roups. Similarly, the appearance of hemosiderosis was 
not significantly different between operate'3 ~r J ro--or- 
erated patients. Neither of these disorders was present 
in a sizeable fraction of the patients under consideration. 
A positive family history of diabetes was found in 
20 (27,3%) of 72 patients in the Ooerated Group as com¬ 
pared with 15 (14.6%) of 103 in the Kon-Operated Group. 
Furthermore, it was observed that of those 20 operated 
patients with a positive family history, nine (45%) went 
on to develop diabetes, while only 12 (23%) of the 52 
operated patients without a oositive family history devel- 
x 
oped diabetes (J( = 2.38 pj> 0.05). Conversely, three (20%) 
of 15 non-operated patients with a positive family history 
of diabetes developed diabetes compared with 13 (14.8%) 
of the 88 non-operated patients without family history of 
diabetes, who developed this disease. These findings 
suggest that the majority of post-shunt diabetes occurs 
in cirrhotic patients with a predisposition to diabetes 
precipitated by some factor which is induced or increased 
by the creation of the PCA. 
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Were the Features of Cirrhosis Similar in the patients 
with and Without Diabetes? 
As seen in Table 12 * the features of cirrhosis were 
similar comparing all diabetic patients with all non¬ 
diabetic patients. There was no significant difference 
in the physical signs of cirrhosis or in the liver function 
studies. This similarity suggests that no one clinical 
feature of the cirrhosis was obviously associated with 
the development of diabetes. A positive family history 
of diabetes was found in 12 (31.4%) of 37 diabetic 
patients, compared with 25 (18.1%) of 120 non-diabetic 
patients. This difference is not statistically significant 
(£4= 1.52 p> 0.05), but again affirms the existence 
of genetic factors in the development of diabetes. 
Was the Diabetes Similar in the Operated and hon-Operated 
Groups? (Table 13) 
The diabetes appears tp be similar in both operated 
and non-operated diabetic patients. All patients had 
maturity onset diabetes characterized by fasting hyper¬ 
glycemia and glycosuria. The mean age of onset of 
diabetes was similar in the two groups* The diabetes in 
both groups was mild. About two-thirds of all patients 
were maintained on dietary therapy alone, and about one- 
third were treated with tolbutamide. Only one patient 
in each group was treated with insulin. There was no 
significant difference in the mode of therapy when 
comparing the two groups. The frequency of vascular 
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complications was extremely low and was not significantly 
greater in either of the groups. 
Of operated patients with diabetes, nine (42.8%) 
had a positive family history as opposed to only 3 (18.7%) 
of the non-ooerated patients, Although this difference is 
not significant, this disparity would seem to indicate that 
patients with a positive family history of diabetes are 
more likely to develop diabetes if they have a PCA 
than if they do not, and that probably the PGA plays a 
part in accelerating the development of this disease. 
W hat was the Cumulative Incidence of Diabetes? 
Figure III shows the cumulative occurrence of 
diabetes during the follow-up period. The data used in 
calculating the “life survival'1 curves as shown in 
Figure III are shown in Tables 16 and 17 . These data 
indicate that during the first 24 months post PCA, 
7 (11.5%) of 67 operated patients considered to be at 
risk during this period developed diabetes. During this 
same period, 3 (3.4%) of 38 non-operated patients 
developed diabetes (o^> 0.05). Furthermore, of 11 
patients who developed diabetes after PCA, 7 (64.0%) 
did so during the first 24 months post-op, while during the 
same period only 3 (37.5%) of 8 non-operated patients 
developed diabetes. 
Figure III shows that the cumulative incidence of 
diabetes in non-operated patients assumes a linear 
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distribution, with the incidence maintaining a reasonably 
steady rate throughout the period of follow-up. The 
distribution of diabetes in the operated patients shows 
a steep initial rise in the appearance of diabetes 
from zero to 24 months, followed by a linear pattern which 
closely parallels the curve of the non-operated patients. 
This observation suggests that whatever the mechanism of 
PCA-precipitated diabetes, it apparently acts rapidly on 
most of its targets. 
Of the seven patients who developed diabetes within 
24 months of PGA, three had a positive family history of 
diabetes (not significant), one patient who had a pre¬ 
operative history of chronic fibrosing pancreatitis and 
was observed to have elevated hepatic hemosiderin 
deposits on biopsy two years post-operatively was also 
found to have diabetes at that time. In the six other 
patients who developed diabetes within 24 months, none 
was found to have evidence of pancreatitis or hemo¬ 
siderosis. Two patients were found to have diabetes 
within two months of surgery which persisted throughout 
the subsequent period of follow-up. In neither case 
could any significant precipitating factor be identified. 
Ana lysis o f Eleven New Cases o_f Diabetes Post Shunt 
Eleven new cases of diabetes were observed after 
PGA, in these studies (Table 15). Analysis of these cases 
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was undertaken in the hope of determining what factors 
contributed to the development of the diabetes. These 
patients develooed diabetes from one to 120 months 
(mean of 20 months) after creation of a PCA. The mean age 
of onset of diabetes was 45 years. Four of the 11 had a 
positive family history of diabetes, and three had hemo¬ 
siderosis. One had pancreatitis and one was found to have 
a carcinoma of the pancreas. The diabetes in these patients 
was relatively homogeneous. In most it was mild, without 
ketosis. Insulin therapy was required in two patients. 
One patient had peripheral arterial insufficiency requiring 
amputation, no other patients exhibited arterial insuf¬ 
ficiency. Several pathogenetic factors must be considered 
in these patients. 
Deterioration of Liver Function. It is well esta¬ 
blished that hepatic blood flow falls after construction 
of portacaval shunts in man.(32) It is also known that 
in patients with PGA, hepatic failure is the most common 
cause of death.(35,36) In our patients however, deter¬ 
ioration of liver function after PGA was not consistently 
a problem. Three patients (P.D., 3.R., and J.V.) died 
of hepatic failure at 116, 56, and 141 months post opera¬ 
tively. These same three had developed diabetes 37, 48, 
and 120 months respectively post PCA. In none of the cases 
however, were liver function tests significantly changed 
from pre-shunt values at the time diabetes was first 
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recognized. On the other hand liver function imoroved 
in several patients after PGA. In general liver function 
has been found to deteriorate in one third, remain stable 
in one third, and improve in one third of patients after 
PGA. Our data in these 11 patients do not implicate fail¬ 
ing hepatic function as a precipitating factor in the 
development of post shunt diabetes. 
Hemosiderosis. The full blown hemochromatotic 
syndrome has been reported to develop rapidly after 
construction of a portacaval anastomosis.(20) Three of 
our 11 patients were found to have post shunt hemosider¬ 
osis. In all three it is probable that the hemosiderosis 
played a role in the development of diabetes. In two 
of these patients (F.B. and 3.11.), diabetes and hemosider¬ 
osis were first recognized at approximately thr samjS time, 
while in the third (J.V.), the hemosiderosis preceeded the 
onset of diabetes by three years. In the cases of F.B. and 
B.Pv. the presence of a persistent hyperlipemia along with 
the hemosiderosis may also have played a role in the 
precipitation of diabetes. It is interesting that of the 
three cases of post shunt hemosiderosis, only one occurred 
during the period of peak incidence of post shunt diabetes. 
The other two were noted four and seven years after surgery. 
Contrastingly, none of the eight patients who developed 




Pancreatitis. Only one patient (F.B.), who developed 
diabetes post-ooeratively had had overt pancreatitis. He had 
had a long history of chronic recurrent pancreatitis prior 
to PGA. Two years after PGA he became diabetic and at the 
same time was found to have hemosiderosis on liver biopsy. 
In this case it is not clear which of these factors was 
primary. Probably all participated, pancreatitis is the 
most attractive possibility since pancreatitis is associa¬ 
ted with iron absorption and hemosiderosis. There was no 
evidence of pancreatitis in the other patients, and it 
would appear that diabetes after PGA can not be related 
to pancreatitis. It is interesting to note that one 
patient (W.P.) developed carcinoma of the pancreas which 
was discovered 114 months after surgery. This patient was 
found to have persistent fasting hyperglycemia about six 
months prior to the diagnosis of the carcinoma. In this 
case the neoplastic invasion of the pancreas was probably 
responsible for the patient’s diabetes. 
Kaliopenia. We have found no evidence that potassium 
depletion is more severe after PGA than before. In fact 
it was our impression that hypokalemia was much less 
common in shunted than non-shunted patients. There is no 
evidence in the Literature that potassium depletion is 
accelerated as a result of PCA. It seems unlikely that the 




What Other Factors Might be Responsible? Five post 
shunt diabetics were not found to ha^/e any recognized 
diabetogenic factor. Four of the five developed diabetes 
within 20 months after PGA.. In these cases with no 
identifiable precipitating factor, insulin resistance 
aggravated by PCA may have played a role in the development 
of diabetes. 
Insulin resistance may be related to shunting of 
insulin from portal to systemic circulation, normally 
about half of the insulin secreted into the portal vein 
is degraded by the liver during its initial passage through 
the liver.(42) The resultant hyperinsulinemia might 
decrease target organ sensitivity by inducing tolerance 
to insulin which in turn could lead to further insulin 
production until islet cell exhaustion interrupted this 
vicious cycle. 
While all of our patients both operated and unoper¬ 
ated had spontaneous portal-systemic shunting before 
surgery, the shunting was increased following PGA. This 
increased shunting of blood may sufficiently accelerate 
the shunting of insulin to precipitate islet cell failure. 
Islet cell exhaustion may also be brought about 
through increasing demands for insulin secondary to the 
shunting of glucose around the liver, although this is 
probably a much less important factor. In patients with 
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portal-systemic shunting of blood, orally ingested glu¬ 
cose, a large fraction of which is normally removed in 
its initial passage through, will bypass the liver and 
enter the systemic circulation.(43) The post prandial 
hyperglycemia so produced might further increase the 
demand for insulin as well as further stimulate the cells 
to produce insulin. 
Paradoxically, a beneficial effect of PGA, has 
occasionally been observed in patients who already have 
diabetes. Several observers have reported improvement in 
glucose tolerance after PGA.(31,44) Conn found that 
glucose tolerance deteriorated in most cirrhotic patients 
after PCA, but that in all three cirrhotic patients with 
diabetes whom he studied, glucose tolerance improved 
after the shunt.(37) We observed one patient inwhom PCA 
was followed by a sustained disappearance of hypergly¬ 
cemia and glycosuria. 
The mechanism by which PCA may improve diabetes 
has been explored by LaVeen and his associates. He demon¬ 
strated that dck fistulas corrected diabetes in dogs 
rendered diabetic by partial pancreatectomy(45) Presumably 
by avoiding hepatic degradation of insulin in its first 
passage through the liver, Samaan(23) and others have 
shown that insulin secretion, as determined by serum 
insulin levels after glucose administration, is greatLy 
increased by PCA. The creation of a portacaval shunt in 
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a diabetic patient may be equivalent to a sizeable increase 
in output by the pancreas. 
Although it is conceivable that a single mechanism 
is responsible for post shunt diabetes, it is more likely 
that this syndrome may arise in a variety of ways. 
Genetic predisposition plays a role but it is not the only 
role, or even the major one. Until a reliable genetic 
marker to detect predisposition to diabetes is found, 
the genetic aspects of diabetes must remain speculative. 
Hepatic hemosiderin deposition, which is increased by 
PCA, seemed to play a role in some patients, but not all. 
In other patients diabetes may have developed as the result 
of secondary, non-hepatic, non-shunt related causes such 
as neoplastic or inflammatory injury or destruction of the 
islets of Langerhans. The majority of our cases revealed 
no clues. One must conclude, therefore, that there may 
be many causes of diabetes after portacaval anastomoses, 
that these factors may act in concert, and that the critical 




The association of diabetes with portacaval anasto¬ 
mosis was investigated in a group of 93 cirrhotic patients 
with PCA, Diabetes was significantly more common (21 of 72 
followed 27.3%) in this group than in a control group of 
non-operated cirrhotic patients (16 of 103, 15.5%) Consider 
ing only those patients who developed diabetes after PCA, 
a similar trend was observed (11 of 62, 17.7% operated vs. 
8 of 95, 9.5% control), although this was slightly less 
significant. 
The diabetes in both those with PCA and non-operated 
controls was maturity onset in type, characterized by 
fasting hyperglycemiaJ minimal glycosuria, relative free¬ 
dom from vascular complications, and simple management with 
diet or oral agents. Although the features of cirrhosis 
were similar in ooerated and non-operated patients a his¬ 
tory of diabetes in the immediate family (28% vs. 15%) was 
far more common among those with PCA, 
Analysis of the 11 patients who developed diabetes 
after PCA revealed that this group was not significantly 
different from the others in severity of cirrhosis and type 
of diabetes. Several diabetogenic factors were found to 
be operative in this grouD but these were not found to be 
present to a greater degree than that which was observed in 
the other grouns. These disorders commonly associated with 
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chronic liver disease could result in diabetes of hepa¬ 
togenous, pancreatitic, hemosiderotic, kaliopenic, insulin 
resistant, somatotropic, or genetic origin. 
The data suggest that while no single factor can be 
elucidated, PCA may precipitate diabetes in susceptible 
patients through the potentiation of a number of disorders 
commonly associated with cirrhosis and may even by itself 
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TABLE 1 , CASS REPORTS OF DIA3E TSS APPEARING 
AFTER PORTACA .VAL A RASTA MOSES 




Hearn, G. 1 1963 1 34 F. 5 Pancreatic 
islet cell 





et, al. 2 1965 3 49 M. 19 Pancreatic 
islet cell 
exhaustion 
Bernardes, P,, 3 1966 4 55 M. 7 pancreatic 
et, al. disease 
5 40 M. 3.6 Pancreatic 
disease 
Christensen, 4 1967 6 41 M. 14 "Possible 
M. F. 
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TABLE 1L. COMPARISON OF FEATURES OF CIRRHOSIS 
IN OPERATED AND N0N-0PERAT2D GROUPS 





No. of patients 
followed 
103 72 
Mean age az 
inclusion (yrs.) 
51.0 . 50.5 N.S.* 
Family history of 
diabetes 
15 (14.6%) 20 (27.8%) "4% 3.84 
p< 0.05 
Physical signs of 
Cirrhosis 
Hepatomegaly 97.5% 98.5% N.S. 
Splenomegaly 47.5% 41.5% N.S. 
Jaundice 48.0% 44.0 % N.S. 
Spider angiomata 64.0% 66. 77o N.S. 
.Ascites 64.5% 66. 7% N.S. 
Liver Function Studies 
Serum albumin 
(s/%) 
2.8 3.0 N.S. 
SCOT (Reitman- 
Franke 3. units) 





14.7 13.5 N.S. 
N.S* = Not significant 
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TABLE 12. COMPARISON OF CLINICAL FEATURES OF CIRRHOSIS 
IN DIABETIC AND NON-DIABETIC PATIENTS 
Clinical Feature Diabetic Non' -Diabetic Statistical 
Significance 
No, of pts. followed 37 133 
Mean age at inclusion 52.5 50.5 N.S.* 
Family history of 
diabetes 
12 (31,4%) 25 (18.1%) N.S. 
Physical Findings 
prior to inclusion 
Snider Angiomata 32.6% 45.3% N.S. 
Ascites 47.0% 6 6,0% N.S. 
Hepatomegaly 100.0% 97.5% N.S. 
Splenomegaly 53.2% 42.7% N.S. 
Liver Function Studies 
Serum Albumin 
( §//«) 
3.1 2.9 N.S. 
SCOT (Reitman- 
Fr ank e1 units) 




14.3 17.0 N.S. 
*N.S. = Not Significant 
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TABLi 13. COMPARISON 0? CLINICAL FEATURES OF 









No. of diabetic 21 16 N.S.* 
patients 
Mean age at inclusion 52.0 53.0 N.3. 
(years) 
Mean age at onset of 51.0 54.5 N.S. 
diabetes (years) 
Family history of 9 (42.8%) 3 (18.7%) N.S. 
diabetes 
Pancreatitis 1 (4.3%) 1 (6.2%) N.S. 
Hepatic Hemosiderosis 4 (19.0%) 0 (0%) N.S. 
Glycosuria 18 (83.3%) 14 (87.5%) N.S. 
Transient diabetes 1 (4.8%) 2 (13.3%) N.S. 
Therapy employed 
Insulin 2 (16.7%) 1 (6.2%) N.S. 
Tolbutamide 7 (33.3%) 3 (20.0%) N.S. 
Diet only 13 (62.0%) 12 (75.0%) N.S. 
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APPENDIX A. DATA COLLECTION SHEET 



























CARBOHYDRATE TOLERAK C E 
S P UDIE3 
FB3 
DATES 
Date of inclusion 
Date of shunt 
Latest study 
Onset of cirrhosis 
Onset of diabetes 
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